News
Studies Mixed on Second Cancers After Lenalidomide
- Author:
- Neil Osterweil
Major Finding: At a median follow-up of 30 months, 12 of 150 (8%) patients on melphalan-prednisone plus lenalidomide with maintenance developed an...
News
Chemo Length May Not Affect Survival in Some B-cell Lymphomas
- Author:
- Neil Osterweil
Major Finding: The 2-year overall survival rates were 81% in the R-CHOP-21 arm, and 83% in the R-CHOP-14 arm (log rank P = .70).
News
Transplant in First Remission Holds Off Progression in Non-Hodgkin's Lymphoma
- Author:
- Neil Osterweil
Major Finding: Estimated 2-year progression-free survival was 69% among patients randomized to CHOP chemotherapy with/without rituximab plus...
News
Transplant in First Remission Holds Off Progression in Non-Hodgkin's Lymphoma
- Author:
- Neil Osterweil
Major Finding: Estimated 2-year progression-free survival was 69% among patients randomized to CHOP chemotherapy with/without rituximab plus...
News
Transplant in First Remission Holds Off Progression in Non-Hodgkin's Lymphoma
- Author:
- Neil Osterweil
Major Finding: Estimated 2-year progression-free survival was 69% among patients randomized to CHOP chemotherapy with/without rituximab plus...
News
Transplant in First Remission Holds Off Progression in Non-Hodgkin's Lymphoma
- Author:
- Neil Osterweil
Major Finding: Estimated 2-year progression-free survival was 69% among patients randomized to CHOP chemotherapy with/without rituximab plus...
News
Platinum Monotherapy Active Against Metastatic Triple-Negative Breast Cancer
- Author:
- Neil Osterweil
Major Finding: Among patients with metastatic triple-negative breast cancers, single-agent therapy with cisplatin or carboplatin produced an...
News
Protein Expression Marker May Predict Response to Anthracyclines
- Author:
- Neil Osterweil
Major Finding: Overexpression of TOP2A protein in breast cancer was found to be predictive of response to anthracyclines, independent of HER2 gene...
News
Protein Expression Marker May Predict Response to Anthracyclines
- Author:
- Neil Osterweil
Major Finding: Overexpression of TOP2A protein in breast cancer was found to be predictive of response to anthracyclines, independent of HER2 gene...
News
New Cancer Patients Struggle to Get Appointments
- Author:
- Neil Osterweil
Major Finding: Research assistants posing as patients with inoperable hepatocellular carcinoma got new-patient appointments only 23% of the time....
News
New Cancer Patients Struggle to Get Appointments
- Author:
- Neil Osterweil
Major Finding: Research assistants posing as patients with inoperable hepatocellular carcinoma got new-patient appointments only 23% of the time....
News
New Cancer Patients Struggle to Get Appointments
- Author:
- Neil Osterweil
Major Finding: Research assistants posing as patients with inoperable hepatocellular carcinoma got new-patient appointments only 23% of the time....
News
New Cancer Patients Struggle to Get Appointments
- Author:
- Neil Osterweil
Major Finding: Research assistants posing as patients with inoperable hepatocellular carcinoma got new-patient appointments only 23% of the time....
News
Carboplatin Adds No Benefit to Standard Therapy for Basal-Like Breast Cancer
- Author:
- Neil Osterweil
Major Finding: The pCR rate in basal-like breast cancer was 35% for standard chemotherapy with epirubicin, cyclophosphamide, and docetaxel, and 30...
News
Crizotinib Continues to Produce High Response in ALK+ NSCLC
- Author:
- Neil Osterweil
Major Finding: In an ongoing phase I trial, the overall response rate to crizotinib was 61%, and the median duration of response was 48 weeks.Data...